Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net)
Ring, Kyle Smuk, Melanie Shongwe, Moses Okonta, Leroy Mackie, Nicola E Ayres, Sara Barber, Tristan J Akodu, Jane Ferro, Filippo Chilton, Daniella
Ring, Kyle
Smuk, Melanie
Shongwe, Moses
Okonta, Leroy
Mackie, Nicola E
Ayres, Sara
Barber, Tristan J
Akodu, Jane
Ferro, Filippo
Chilton, Daniella
Citations
Altmetric:
Affiliation
Barts Health NHS Trust; Queen Mary University of London; Imperial College Healthcare NHS Trust; Royal Free London NHS Foundation Trust; Institute for Global Health; Guy's and St Thomas' NHS Foundation Trust; Liverpool University Hospitals NHS Foundation Trust; Cardiff and Vale University Health Board; Walsall Healthcare NHS Trust; Chelsea and Westminster Hospital NHS Foundation Trust; Havering and Redbridge University Hospitals NHS Trust; Blackpool Teaching Hospitals NHS Foundation Trust; Newcastle upon Tyne Hospitals NHS Foundation Trust; Central and North West London NHS Foundation Trust
Other Contributors
Publication date
2024-10-01
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Introduction: Long-acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics.
Methods: Centres populated a database using information from local policies and clinical records. Services were asked to describe approval processes, clinic pathways, and adherence to national guidelines. Additional data were collected on reasons for regimen choice, treatment discontinuations, and management of viraemia.
Results: In total, 518 adults from 12 clinics were approved for CAB + RPV LAI between February 2022 and December 2023. Of the 518 people approved for CAB + RPV LAI, 423 received at least one injection. Median duration on CAB + RPV was 7.5 months (interquartile range 3.7-11.3). In total, 97% of injections were administered within the ±7-day window. Virological failure occurred in 0.7%, and 6% discontinued CAB + RPV.
Conclusion: In this large UK-based cohort, robust approval processes and clinic protocols facilitated on-time injections and low rates of both discontinuation and virological failure.
Citation
Ring K, Smuk M, Shongwe M, Okonta L, Mackie NE, Ayres S, Barber TJ, Akodu J, Ferro F, Chilton D, Hurn E, Halai B, Barchi W, Ali A, Darko S, White G, Clarke E, Clark F, Ali B, Arumainayagam J, Quinn G, Boffito M, Byrne R, Naous N, Leung S, Umaipalan A, Thornton B, Bayliss D, McLoughlin C, Foster J, Waters L, Orkin C. Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net). HIV Med. 2024 Oct;25(10):1125-1134. doi: 10.1111/hiv.13679. Epub 2024 Jun 10. PMID: 38858222.
Type
Article